MNTA: Small milestone for M-enox: 10Q
"In addition to commercial revenues associated with the sale of enoxaparin sodium injection, in our financial statements for the quarter ended September 30, 2010, we expect to record $5.0 million in revenue related to the achievement of a regulatory milestone defined in the 2003 Sandoz Collaboration"
"If we don't succeed, we run the risk of failure."
-Dan Quayle